Zydus Lifesciences is set to be in focus after it received tentative approval from the United States Food and Drug Administration for Empagliflozin and Linagliptin combination tablets for type 2 diabetes, alongside final approval for a blood pressure treatment drug. The company also entered into a licensing and commercialisation pact with RK Pharma for a supportive oncology product in the US. Shares ended marginally lower on Thursday as investors assessed the latest regulatory developments.
Zydus Lifesciences shares in focus after US FDA nods for diabetes and blood pressure drugs
📅 Published: November 28, 2025 |
📂 Category: Uncategorized